Next Phase Newsletter

A venture arm of a pharmaceutical company is looking to make investments around $3 million in companies in the life science space. The firm could make as many as 2-3 investment over the next year and is willing to allocate to companies located around the globe. Besides equity investment, the firm would consider local licensing opportunities.

The firm is currently looking for companies developing therapeutics and is open to small molecules, biologics, and cell/gene therapy. The team is more interested in companies working with single assets although they can consider platform technologies. Indications of interest include Oncology, Inflammation, Orphan diseases, Critical care, Ophthalmology and Autoimmune diseases. The firm tends to be agnostic though and in spite of these focuses, is willing to look at most projects. The team looks for companies that have at least reached in-vivo proof of concept with their lead asset.

The firm looking for privately held companies and prefers companies with experienced management teams in place. The team looks to act as a value-added investor through their strategic alignment with their parent company, and looks to take a seat on the company’s board on a case by case basis. The firm is willing to both lead and co-invest in financing rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the USA  has two funds under management and is currently investing out of its second fund. The firm seeks to make equity investments into life science companies from early to late stages. The typical investment size ranges from $2 million to $4 million. The firm plans to invest in 2-3 companies over the next 12 months and prefers to invest in companies based in US or Canada.

The firm is currently looking for new investment opportunities in life sciences.  The firm is primarily focused on clinical stage biotech opportunities, and will consider any indication area.  The firm prefers to invest in platform technologies rather than single asset companies.

The firm generally seeks to invest in private companies. The firm has no specific requirements for the company’s management team, and sometimes takes a board seat when investing.  For therapeutics, Excel looks for companies that are developing platform technologies but have a clear plan on moving the lead program forward.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A professional firm provides management consulting and investment banking services in international corporate development to high technology companies.  The firm has been active in the healthcare sector for over 20 years working with Japanese clients that are looking for new business and/or technology opportunities both in medical device and pharmaceutical sectors. Currently, the firm does not manage its own VC funds but has access to funds prepared for direct investments or through CVCs by the firm’s clients in Japan. The firm is interested in companies from the seed stage through to late-stage venture rounds. The size of Investments varies by stage ranging from $0.5 Million to $3 Million. The firm is particularly interested in companies that have strong strategic fit with the Japanese market.

The firm’s primary focus is on the intersection between IT and Life Science, including POCT, telemedicine, among others.  Technologies involving sensors and materials science are also high focus areas.  For therapeutics, the firm generally does not invest in single-asset companies; therapeutic platform technologies that have the potential to create multiple ‘shots on goal’ are preferred.  The firm focuses on patients for whom there is high unmet need and no currently adequate treatments.  Rare diseases are of high interest.

The firm seeks management teams that exhibit knowledge of how to create a corporate value out of a strong technology.  The firm focuses on technologies that allow the firm’s clients to provide a value-add in joint R&D, manufacturing, or distribution.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The firm is a venture capital firm based in the Netherlands, which is entirely specialized in and focused on investing in early-stage oncology drug development companies. Through its Oncology Funds I and II, the firm has invested in 13 early stage companies, of which 6 were founded by the firm. The firm is no longer investing out of their Oncology Fund II and is in the process of closing their Oncology Fund III. For its third fund, the firm seeks to invest in an estimated 10 biotechnology start-ups in cancer treatment. Typical investments are made in equity and with an average ticket size of 10 million Euros over a period of 5 to 7 years. In addition, the seeks to invest 1-2 million Euros in promising academic cancer research projects over a period of 18 months with the aim to transition these projects to New Cos. The firm seeks a lead investor role in companies based in the Netherlands and Belgium, and a co-investor role in other regions. The firm prefers syndicated investments with like-minded investors with equal ticket sizes. The firm’s main focus is on European companies, although they will consider US opportunities.

The firm focuses on a wide spectrum of cancer treatment, including but not limited to small molecules, antibodies, gene therapy, cell therapy, and immunotherapy. The firm supports early-stage companies from incubator stage and preclinical through phase 1. The firm prefers to invest in companies that have underlying platform technologies.

The firm can support management teams by being operationally involved on an interim basis in companies based in the Netherlands, and will frequently set-up companies from scratch with the inventors. The firm can help refine the business plan, R&D plans and provide financial, IP, IT, legal, HR support. If needed, the firm will take up interim-management roles.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a corporate venture firm located in Wisconsin. The firm is on its second fund of $150M, and has 4 area of focus: fintech, digital health, data analytics and insurtech. The firm has made 36 investments total and the average check size is around $1M in Seed or Series A rounds. The firm’s capital structure is typically SAFEs and priced rounds. The firm also has a second venture fund of $5M for Pre-seed and Seed rounds, and this fund is exclusively for companies located in Wisconsin. The firm invests across the US and Canada.

The firm’s main areas of focus are fintech, digital health, data analytics and insurtech. Since the firm is a branch of a legacy life insurance company, within the insurtech and fintech sectors, the firm focuses on the evolution of the consumer wallet and how they can develop new products in partnership with startups. Within the digital health sector, the firm focuses on data collection and items that can influence their underwriting models, electronic med records, wearables, remote monitoring devices, and the firm is looking more into implantables in the future. The firm isn’t interested in physician scaling tools, or any companies focused solely on hardware. The firm is open to pre-prototype companies.

The firm looks for diverse management teams, with 2 or 3 founders. The firm likes to see subject matter expertise, traction in product development or alpha/beta testing, and repeat founders are a plus, but not required. The firm also looks for a strong advisor team. The firm typically co-invests.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The fund is a new $125M fund jointly founded by a New York-based firm and a Korea-based firm in 2021. The New York based firm is a global investment banking and strategic advisory firm specialized in life sciences, with decades of experience in supporting multiple leading life science companies. The Korea-based firm is a subsidiary of a leading Korean venture capital firm with over 30 years of investment experience. The firm seeks to invest between $2-10M (over the company’s lifespan) in therapeutics and medical device companies, with its sweet spot being Series A financings. The firm is actively sourcing deals globally with a focus on USA.

The fund seeks to invest 80% in therapeutics and 20% in medical devices. Indication-wise, the firm is most interested in oncology, CNS, cardiovascular, and rare diseases. The firm expects companies to already be conducting IND enabling studies or are currently running clinical trials. The firm will consider all types of modalities. The firm also has a broad interest in all types of medical devices, from traditional devices to cell therapy equipment, and will consider devices of all regulatory pathways including 510k and PMA.

The fund has no specific company or management team requirements. The firm is open to leading, co-leading, and co-investing, and will seek board representation when they act as the lead investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

An early-stage VC fund founded in 2011 by a group of alumni from Tsinghua University is based in Los Altos, California. The group currently has $100M, under management. The group focuses on Angel to Series B stage companies across various sectors, including pharmaceutical, medical device, services and tools, and digital health. The typical investment size is between $1M to $2M. The group also syndicates with other investors for larger investments. The firm looks to make investments across the globe.

The firm is currently looking for new opportunities in the life science space. The fund is opportunistic in terms of sectors, subsectors and indications. The fund typically invests in seed rounds and series A rounds. Historically, the fund has been active in life science companies developing innovative platform technologies and cross-disciplinary technologies.

The firm focuses on investments in private companies and typically invests in pre-clinical and early clinical stage companies with strong and experienced management teams. The firm will take a board seat or observer seat occasionally, depending on the investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.